EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Development of CD73 Inhibitors in Tumor Immunotherapy and Opportunities in Imaging and Combination Therapy

Chunyang Bi, Jimmy S Patel, Steven H Liang iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02151 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Chunyang Bi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia 30322, United States. Hauptthemen laut MEDLINE: 5'-Nucleotidase, Neoplasms, Immunotherapy, Enzyme Inhibitors. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, School of Medicine, Emory University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD73 is a member of the membrane-bound enucleotidase family, which catalyzes the extracellular hydrolysis of adenosine monophosphate (AMP) to produce anti-inflammatory and immunosuppressive adenosine. As a novel checkpoint protein, CD73 is overexpressed in the immune system of various tumors, where adenosine is abundantly enriched. A large number of monoclonal antibodies (mAbs), nucleotides, and non-nucleotides as potent CD73 inhibitors are being discovered, providing opportunities for novel tumor immunotherapy. Currently, 18 CD73 inhibitors are in clinical trials, showing promising results in combination therapy for various solid tumors. The development of CD73-specific companion positron emission tomography imaging ligands holds potential for facilitating diagnosis, patient selection, and treatment efficacy evaluation throughout the entire process of CD73-targeted therapeutic development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

5'-NucleotidaseNeoplasmsImmunotherapyEnzyme InhibitorsHumansAnimalsGPI-Linked ProteinsAntibodies, MonoclonalPositron-Emission Tomography

Substanzen

5'-NucleotidaseNT5E protein, humanGPI-Linked ProteinsAntibodies, MonoclonalEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia 30322, United States.
  • PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.
  • Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, United States.
  • Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, United States.

ORCID-Profile: Steven H Liang

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • School of Medicine, Emory University
  • Emory Radiology Chair Fund

Zitieren

APA

Bi, C., Patel, J. S., & Liang, S. H. (2025). Development of CD73 Inhibitors in Tumor Immunotherapy and Opportunities in Imaging and Combination Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02151

Vancouver

Bi C, Patel JS, Liang SH. Development of CD73 Inhibitors in Tumor Immunotherapy and Opportunities in Imaging and Combination Therapy. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02151

BibTeX
@article{Bi2025,
  author = {Bi, Chunyang and Patel, Jimmy S and Liang, Steven H},
  title = {Development of CD73 Inhibitors in Tumor Immunotherapy and Opportunities in Imaging and Combination Therapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02151}
}
Kostenlos starten →